RALY - RALY heterogeneous nuclear ribonucleoprotein Gene
Species: Canis lupus familiaris (sub-species: familiaris)
Gene Type: protein coding
Gene ID: 485845
RALY Products (5)
| mRNA | Protein | Name |
|---|---|---|
| XM_038433546.1 | XP_038289474.1 | RNA-binding protein Raly isoform X1 |
| XM_038433550.1 | XP_038289478.1 | RNA-binding protein Raly isoform X2 |
| XM_038433548.1 | XP_038289476.1 | RNA-binding protein Raly isoform X1 |
| XM_038433549.1 | XP_038289477.1 | RNA-binding protein Raly isoform X1 |
| XM_038433547.1 | XP_038289475.1 | RNA-binding protein Raly isoform X1 |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
RNA-binding protein Raly |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(11)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-15771 | Tirabrutinib | 99.71% | Yes | |
| HY-P3502 | Zilucoplan | Inhibitor | 99.71% | Unkown |
| HY-B0524 | Betahistine | Modulator | 99.84% | Unkown |
| HY-106019 | Liarozole | Inhibitor | 98.96% | Yes |
| HY-10405 | Pamapimod | Inhibitor | 99.71% | Unkown |
| HY-B0524A | Betahistine dihydrochloride | Modulator | 99.82% | Unkown |
| HY-17509 | Deracoxib | 99.96% | Unkown | |
| HY-15771A | Tirabrutinib hydrochloride | 99.66% | Yes | |
| HY-B0160 | Lafutidine | Antagonist | 99.56% | Unkown |
| HY-D0237 | Betahistine mesylate | Modulator | 99.90% | Unkown |
| HY-P3502A | Zilucoplan TFA | Inhibitor | / | Unkown |
Bioactive MoleculesInhibitory Antibodies
(2)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P9924 | Ixekizumab | Inhibitor | 99.00% | Unkown |
| HY-P99661 | Inbakicept | Activator | 99.06% | Unkown |
Clinical Phase
Bioactive Molecules
(15)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-P10284 | S7 | 98.25% | Phase 4 | |
| HY-10291 | Tarenflurbil | Inhibitor | 99.95% | Phase 3 |
| HY-106019C | Liarozole dihydrochloride | Inhibitor | 99.04% | Phase 3 |
| HY-14531 | Talarozole | Inhibitor | 99.75% | Phase 2 |
| HY-150105 | Icovamenib | Inhibitor | 98.96% | Phase 2 |
| HY-18099A | S1RA hydrochloride | Antagonist | 99.76% | Phase 2 |
| HY-147264 | Edecesertib | Inhibitor | 99.86% | Phase 2 |
| HY-18099 | S1RA | Antagonist | 98.96% | Phase 2 |
| HY-101671 | S-methyl-KE-298 | 98.0% | Phase 2 | |
| HY-109034A | Imarikiren hydrochloride | Inhibitor | / | Phase 2 |
| HY-155031 | MCI | Inhibitor | / | Phase 2 |
| HY-163102 | IA-14069 | Inhibitor | 99.93% | Phase 1 |
| HY-P10935A | Amilo-5MER TFA | Inhibitor | 99.63% | Phase 1 |
| HY-106857A | RA-octil | / | Phase 1 | |
| HY-P10935 | Amilo-5MER | Inhibitor | / | Phase 1 |
Bioactive MoleculesInhibitory Antibodies
(14)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-P99252 | Itolizumab | ≥99.0% | Phase 3 | |
| HY-P990983 | Drotokibart | Inhibitor | 97.05% | Phase 3 |
| HY-P99870 | Eblasakimab | ≥99.0% | Phase 2 | |
| HY-P99259 | Cabiralizumab | Inhibitor | 99.73% | Phase 2 |
| HY-P99385 | Vobarilizumab | Inhibitor | 99.9% | Phase 2 |
| HY-P991424 | GSK2618960 | Inhibitor | 95.66% | Phase 2 |
| HY-P991266 | SM-17 | Inhibitor | 96.98% | Phase 2 |
| HY-P99642 | Gimsilumab | Inhibitor | 98.00% | Phase 2 |
| HY-P991596 | ANB004 | Antagonist | / | Phase 2 |
| HY-P990086 | Vopikitug | Inhibitor | 98.32% | Phase 1 |
| HY-P990647 | PF-06342674 | Inhibitor | 99.69% | Phase 1 |
| HY-P991282 | KHK2823 | Inhibitor | / | Phase 1 |
| HY-P991643 | MTRX1011A | Inhibitor | / | Phase 1 |
| HY-P991937 | SOL-116 | Inhibitor | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(233)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-N0142 | Phloretin | Inhibitor | 99.92% | Unkown |
| HY-108521 | HX531 | 99.87% | Unkown | |
| HY-P10136 | IA9 | Inhibitor | 97.24% | Unkown |
| HY-125099A | AFM-30a hydrochloride | Inhibitor | 99.66% | Unkown |
| HY-147141 | HS-276 | Inhibitor | 98.93% | Unkown |
| HY-111532 | (3R,4R)-A2-32-01 | Inhibitor | 98.47% | Unkown |
| HY-15898 | Y-320 | 99.03% | Unkown | |
| HY-P1848 | Pep-1 (uncapped) | 99.89% | Unkown | |
| HY-N1440 | Koumine | Activator | 99.97% | Unkown |
| HY-N2435 | [8]-Shogaol | 99.93% | Unkown | |
| HY-110275 | RA839 | Inhibitor | 98.54% | Unkown |
| HY-W141394 | Bz-OMe-rA | 99.34% | Unkown | |
| HY-175701 | CT-996 | 99.97% | Unkown | |
| HY-100739 | RA190 | Inhibitor | 99.04% | Unkown |
| HY-164416 | DBCO-Dextran sulfate (MW 40000) | 98.35% | Unkown | |
| HY-173117 | RA306 | Inhibitor | 99.74% | Unkown |
| HY-50081 | CCR2-RA-[R] | Antagonist | 99.21% | Unkown |
| HY-P10136A | IA9 TFA | Inhibitor | 98.90% | Unkown |
| HY-161762 | RA-0002034 | Inhibitor | 99.48% | Unkown |
| HY-N2506 | Ginsenoside Ra1 | 99.88% | Unkown | |
| HY-108522 | PA452 | Antagonist | ≥99.0% | Unkown |
| HY-118530 | Bucillamine | Inhibitor | 99.04% | Yes |
| HY-147972 | NF-κB/MAPK-IN-1 | Inhibitor | 98.71% | Unkown |
| HY-N10790 | RA-V | 99.85% | Unkown | |
| HY-P0207A | Endothelin-2 (49-69), human TFA | Ligand | 99.21% | Unkown |
| HY-21545 | 5'-O-DMT-Bz-rA | 98.0% | Unkown | |
| HY-103046 | UbcH5c-IN-1 | Inhibitor | 99.84% | Unkown |
| HY-15427 | GDC-0834 | Inhibitor | 98.05% | Unkown |
| HY-W006102 | Bz-rA Phosphoramidite | 99.03% | Unkown | |
| HY-136563 | RA375 | 99.87% | Unkown | |
| HY-107730 | NPY5RA-972 | Antagonist | 98.99% | Unkown |
| HY-136528 | RA-9 | 98.57% | Unkown | |
| HY-W008388 | Bz-rA | 99.51% | Unkown | |
| HY-103174 | MRS1334 | Antagonist | 98.93% | Unkown |
| HY-177435 | FAPI-800CW | Inhibitor | 99.40% | Unkown |
| HY-N0142R | Phloretin (Standard) | Inhibitor | 98.15% | Unkown |
| HY-P11287A | DOTA-Pep-1L TFA | Ligand | 98.60% | Unkown |
| HY-W641445 | ELP-004 | Inhibitor | 99.89% | Unkown |
| HY-139314 | A2B receptor antagonist 2 | Antagonist | 99.60% | Unkown |
| HY-P3491 | Pegloxenatide | 90.00% | Unkown | |
| HY-100707 | IC 86621 | Inhibitor | 99.06% | Unkown |
| HY-114221 | Org 48762-0 | Inhibitor | 99.99% | Unkown |
| HY-125099 | AFM-30a | Inhibitor | ≥96.0% | Unkown |
| HY-N10793 | RA-XI | 96.45% | Unkown | |
| HY-N4259 | Ginsenoside Ra3 | 99.91% | Unkown | |
| HY-N4260 | Ginsenoside Ra2 | 99.87% | Unkown | |
| HY-164583 | DMTr-2'-O-C22-rA-3'-CE-Phosphoramidite | 98.0% | Unkown | |
| HY-400730 | 2'-O-POM-rA(Bz) | 99.31% | Unkown | |
| HY-147660 | IMMH001 | Agonist | 98.10% | Unkown |
| HY-103177 | PSB-10 hydrochloride | Inhibitor | / | Unkown |
| HY-104017 | DMT-2'-O-MOE-rA(Bz) phosphoramidite | 98.0% | Unkown | |
| HY-125415 | PF-4693627 | Inhibitor | 99.63% | Unkown |
| HY-135378 | Atorvastatin ethyl ester | 98.16% | Unkown | |
| HY-15427A | GDC-0834 Racemate | 98.04% | Unkown | |
| HY-B0524AS1 | Betahistine-13C,d3 dihydrochloride | Modulator | / | Unkown |
| HY-P0207 | Endothelin-2 (49-69), human | Ligand | 99.86% | Unkown |
| HY-P10292 | NOTA-Pep-1L | 98.60% | Unkown | |
| HY-P10965 | Zovaglutide | Agonist | / | Unkown |
| HY-RS06737 | IL22RA1 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06764 | IL3RA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W018179 | 5'-DMT-3'-TBDMS-Bz-rA | 99.19% | Unkown | |
| HY-13496 | JNJ-28312141 | Inhibitor | / | Unkown |
| HY-21703 | 3'-TBDMS-Bz-rA Phosphoramidite | 98.38% | Unkown | |
| HY-RS18197 | Il17ra Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS29519 | C1ra Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W114886 | DMT-OMe-rA(Bz) | ≥97.0% | Unkown | |
| HY-B0524AS | Betahistine-d3 dihydrochloride | Modulator | 99.0% | Unkown |
| HY-106019A | Liarozole hydrochloride | Inhibitor | / | Unkown |
| HY-106618 | Mopidamol | Inhibitor | / | Unkown |
| HY-107495 | Betahistine EP Impurity C | Modulator | 98.38% | Unkown |
| HY-107644 | AQ-RA 741 | Antagonist | / | Unkown |
| HY-116472 | alpha-RA-F | / | Unkown | |
| HY-118689 | RA-2 | Modulator | / | Unkown |
| HY-118761 | 5,6-Epoxyretinoic acid | Agonist | / | Unkown |
| HY-119291 | RA642 | Inhibitor | / | Unkown |
| HY-120785A | SR1555 hydrochloride | Antagonist | / | Unkown |
| HY-121500 | R-116010 | Inhibitor | / | Unkown |
| HY-123019 | RA-263 | / | Unkown | |
| HY-126640 | Phomoxanthone A | Inhibitor | / | Unkown |
| HY-126862 | AQ-RA 721 | Antagonist | / | Unkown |
| HY-127150 | Clofezone | Inhibitor | / | Unkown |
| HY-13496A | JNJ-28312141 hydrochloride | Inhibitor | / | Unkown |
| HY-135453 | (-)-Pinocembrin | Inhibitor | / | Unkown |
| HY-139654 | α/β-Hydrolase-IN-1 | Inhibitor | / | Unkown |
| HY-143290 | Antibacterial agent 118 | Inhibitor | / | Unkown |
| HY-146104 | Antimycobacterial agent-1 | Inhibitor | / | Unkown |
| HY-147141A | HS-276 hydrochloride | Inhibitor | / | Unkown |
| HY-147141B | HS-276 formic | Inhibitor | / | Unkown |
| HY-14750 | Rabeximod | / | Unkown | |
| HY-148543 | FC-99 | Inhibitor | / | Unkown |
| HY-149064 | Antituberculosis agent-9 | Inhibitor | / | Unkown |
| HY-149581 | DprE1-IN-9 | Inhibitor | / | Unkown |
| HY-150658S | DMT-2′O-TBDMS-rA(ac) phosphoramidite-15N | / | Unkown | |
| HY-150658S1 | DMT-2′O-TBDMS-rA(ac) phosphoramidite-13C2 | / | Unkown | |
| HY-150658S2 | DMT-2′O-TBDMS-rA(ac) phosphoramidite-13C3 | / | Unkown | |
| HY-150658S4 | DMT-2′O-TBDMS-rA(ac) phosphoramidite-13C10 | / | Unkown | |
| HY-150658S5 | DMT-2′O-TBDMS-rA(ac) phosphoramidite-13C10,15N5 | / | Unkown | |
| HY-150658S6 | DMT-2′O-TBDMS-rA(ac) phosphoramidite-15N5 | / | Unkown | |
| HY-150658S7 | DMT-2′O-TBDMS-rA(ac) phosphoramidite-d9 | / | Unkown | |
| HY-151472 | hCAIX/XII-IN-6 | Inhibitor | / | Unkown |
| HY-152035 | Mycobacterial Zmp1-IN-1 | Inhibitor | / | Unkown |
| HY-153333 | A1/A3 AR antagonist 3 | Antagonist | / | Unkown |
| HY-153489 | ISIS 329993 | Inhibitor | / | Unkown |
| HY-153489A | ISIS 329993 sodium | Inhibitor | / | Unkown |
| HY-154961 | Mcl-1 inhibitor 14 | / | Unkown | |
| HY-154962 | Mcl-1 inhibitor 15 | Inhibitor | / | Unkown |
| HY-161762A | (E/Z)-RA-0002034 | Inhibitor | / | Unkown |
| HY-163533 | CPD-002 | Inhibitor | / | Unkown |
| HY-163750 | KMU-11342 | Inhibitor | / | Unkown |
| HY-167905 | ATL444 | Antagonist | / | Unkown |
| HY-170806 | ERα degrader 12 | Degrader | / | Unkown |
| HY-172176 | RA-PR058 | Inhibitor | / | Unkown |
| HY-173321 | PAD4-IN-5 | Inhibitor | / | Unkown |
| HY-173518 | SIN 14 | / | Unkown | |
| HY-175310S | Voderdeucitinib | Inhibitor | / | Unkown |
| HY-176251 | CBP/p300-IN-22 | Inhibitor | / | Unkown |
| HY-176755 | CCL-34 | Activator | / | Unkown |
| HY-178230 | EVT-401 | Agonist | / | Unkown |
| HY-178714 | JNJ627 | Inhibitor | / | Unkown |
| HY-179173S | DMT-2′O-TBDMS-rA(ac) phosphoramidite-13C | / | Unkown | |
| HY-181499 | RA190-PEG1-NH2 | / | Unkown | |
| HY-181523 | RA183 | Ligand | / | Unkown |
| HY-181524 | RA183-CO-C6-NHCO-NH-Boc | Ligand | / | Unkown |
| HY-182415 | RX-RA-69 | Inhibitor | / | Unkown |
| HY-50084 | CCR2-RA | Antagonist | / | Unkown |
| HY-B0160S | Lafutidine-d10 | Antagonist | / | Unkown |
| HY-D2279 | NFL-NH2 | / | Unkown | |
| HY-N11226 | Ginsenoside Ra0 | / | Unkown | |
| HY-N11646 | Ganorbiformin B | Inhibitor | / | Unkown |
| HY-N11650 | (22S,24E)-3β,22-Diacetoxylanosta-7,9(11),24-trien-26-oic acid | Inhibitor | / | Unkown |
| HY-N11957 | Angeloylbinankadsurin A | / | Unkown | |
| HY-N12648 | Anemarsaponin E1 | / | Unkown | |
| HY-N16465 | Cinnamtannin D1 | Inhibitor | / | Unkown |
| HY-N19123 | Ginsenoside Ra9 | / | Unkown | |
| HY-N3612 | Communic acid | Inhibitor | / | Unkown |
| HY-P11046 | IIIM1 | Modulator | / | Unkown |
| HY-P11287 | DOTA-Pep-1L | Ligand | / | Unkown |
| HY-P2045 | RA-VII | / | Unkown | |
| HY-P2642 | Peptide 78 | 98.13% | Unkown | |
| HY-RS03232 | CSF2RA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06673 | IL10RA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06676 | IL11RA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06688 | IL13RA1 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06689 | IL13RA2 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06693 | IL15RA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06702 | IL17RA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06732 | IL20RA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06738 | IL22RA2 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06747 | IL27RA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06748 | IL2RA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06755 | IL31RA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06773 | IL5RA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS11635 | RALY Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-U00449A | AGN 193109 sodium | Antagonist | / | Unkown |
| HY-W748468 | 6-Isopentenyloxyisobergapten | Inhibitor | / | Unkown |
| HY-104017R | DMT-2'-O-MOE-rA(Bz) phosphoramidite (Standard) | / | Unkown | |
| HY-105934A | Ketotrexate sodium | / | Unkown | |
| HY-113721 | BML-244 | Inhibitor | / | Unkown |
| HY-125068 | RPR203494 | Inhibitor | / | Unkown |
| HY-134075 | 2-Amino-2'-O-methyladenosine | / | Unkown | |
| HY-134076 | 2',3'-Di-O-Methyladenosine | / | Unkown | |
| HY-135376 | Atorvastatin methyl ester | 98.76% | Unkown | |
| HY-137007 | SMA-12b | Inhibitor | / | Unkown |
| HY-162707 | RA-0002323-01 | Inhibitor | / | Unkown |
| HY-172397 | Mycobacterium Tuberculosis-IN-7 | Inhibitor | / | Unkown |
| HY-173071 | DprE1-IN-13 | Inhibitor | / | Unkown |
| HY-174601 | Human IL5RA mRNA | / | Unkown | |
| HY-174605 | Human IL3RA mRNA | / | Unkown | |
| HY-174611 | Human IL2RA mRNA | / | Unkown | |
| HY-174612 | Human IL27RA mRNA | / | Unkown | |
| HY-174618 | Human IL22RA2 mRNA | / | Unkown | |
| HY-174619 | Human IL22RA1 mRNA | / | Unkown | |
| HY-174623 | Human IL20RA mRNA | / | Unkown | |
| HY-174632 | Human IL17RA mRNA | / | Unkown | |
| HY-174635 | Human IL15RA mRNA | / | Unkown | |
| HY-174637 | Human IL13RA2 mRNA | / | Unkown | |
| HY-174638 | Human IL13RA1 mRNA | / | Unkown | |
| HY-174643 | Human IL11RA mRNA | / | Unkown | |
| HY-174645 | Human IL10RA mRNA | / | Unkown | |
| HY-174733 | Human CSF2RA mRNA | / | Unkown | |
| HY-176268 | SGC-NSP2hel-1 | Inhibitor | / | Unkown |
| HY-178105 | LQFM326 | Inhibitor | / | Unkown |
| HY-178526 | DMTr-2'-O-Me-6-Deamino-6-(m-benzenepropanoic acid 2-cyanoethyl ester)-rA-3'-CE-phosphoramidite | / | Unkown | |
| HY-178527 | DMTr-2'-O-Me-rA(Bz)-3'-(L)-DPSE-phosphoramidite | / | Unkown | |
| HY-178568 | DMTr-S-5-C-Me-2'-O-Me-rA(Bz)-3'-CE-phosphoramidite | / | Unkown | |
| HY-178595 | DMTr-2'-O-Me-rA(Bz)-3'-(L)-PSM-phosphoramidite | / | Unkown | |
| HY-178599 | DMTr-2'-O-[2-TFAAminoethoxymethyl]-rA(Bz)-3'-CE-phosphoramidite | / | Unkown | |
| HY-178617 | 5'-O-DMTr-2'-O-(2-cyanoethoxymethyl)-rA(Ac) | / | Unkown | |
| HY-178627 | 5'-O-DMTr-2'-O-TOM-rA(Ac) | / | Unkown | |
| HY-178629 | DMTr-2'-O-propyl-rA(Bz)-3'-CE-phosphoramidite | / | Unkown | |
| HY-178632 | 2'-O-Me-7-deaza-rA | / | Unkown | |
| HY-178648 | DMTr-2'-O-Me-rA(Bz)-3'-(D)-DPSE-phosphoramidite | / | Unkown | |
| HY-178652 | 5'-O-Bz-rA(Bz) | / | Unkown | |
| HY-178655 | DMTr-2'-O-C6-rA(Bz)-3'-CE-phosphoramidite | / | Unkown | |
| HY-178660 | DMTr-R-5'-C-Me-2'-O-Me-rA(Bz)-3'-CE-phosphoramidite | / | Unkown | |
| HY-178661 | DMTr-2'-O-TOM-N2-MeOAc-N6-iBu-rA-3'-CE-phosphoramidite | / | Unkown | |
| HY-178669 | 5'-O-DMTr-3'-O-Me-rA(Bz) | / | Unkown | |
| HY-178686 | DMTr-2'-O-Me-rA(Bz)-3'-(D)-PSM-phosphoramidite | / | Unkown | |
| HY-179532 | Antimycobacterial agent-14 | Inhibitor | / | Unkown |
| HY-18016 | CGI 560 | Inhibitor | / | Unkown |
| HY-43049 | DMT-2'O-TBDMS-rA(bz) Phosphoramidite enantiomer | / | Unkown | |
| HY-N12015 | Ginsenoside Ra6 | / | Unkown | |
| HY-N2876 | Anisofolin A | Inhibitor | / | Unkown |
| HY-RS17431 | Il10ra Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS18089 | Csf2ra Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS18438 | Il13ra2 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS18825 | Il2ra Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS19279 | Il13ra1 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS19373 | Raly Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS19696 | Il5ra Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS19780 | Il15ra Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS20169 | Il27ra Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS20557 | Il31ra Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS21241 | Il22ra1 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS21870 | Il20ra Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS23886 | Il10ra Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS24563 | Csf2ra Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS24671 | Il17ra Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS24920 | Il13ra2 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS25315 | Il2ra Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS25769 | Il13ra1 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS25865 | Raly Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS26191 | Il5ra Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS26277 | Il15ra Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS26673 | Il27ra Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS27066 | Il31ra Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS27758 | Il22ra1 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS28387 | Il20ra Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-U00420 | Opioid receptor modulator 1 | Modulator | / | Unkown |
| HY-W1008069 | 3'-TBS-OMe-Bz-rA | / | Unkown | |
| HY-W1121763 | DMT-2'O-TC-rA(bz) Phosphoramidite | / | Unkown | |
| HY-W754015 | 5'-O-DMTr-2'-O-Me-rA | 99.88% | Unkown | |
| HY-W784549 | N6-Me-rA phosphoramidite | / | Unkown |
Bioactive MoleculesInhibitory Antibodies
(27)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P9923A | Benralizumab (anti-IL5RA ) | Inducer | 99.60% | Unkown |
| HY-P990016 | Temtokibart | Inhibitor | 99.23% | Unkown |
| HY-P991219 | Anti-IL11RA Antibody (X209) | Inhibitor | 97.75% | Unkown |
| HY-P990713 | Nolavetbart | 96% | Unkown | |
| HY-P99287 | Elsilimomab | Inhibitor | 98.44% | Unkown |
| HY-P990166 | Anti-Mouse PSGL-1/CD162 Antibody (4RA10) | Inhibitor | ≥95.0% | Unkown |
| HY-P990662 | Sapelizumab | Inhibitor | 98.31% | Unkown |
| HY-P991513 | BI-655064 | Inhibitor | 98.56% | Unkown |
| HY-P990299 | Anti-Mouse B220 Antibody (RA3.3A1/6.1) | Inhibitor | ≥95% | Unkown |
| HY-P99782 | Opinercept | Inhibitor | / | Unkown |
| HY-P991688 | Gimvekibart | Inhibitor | 95.50% | Unkown |
| HY-P991699 | Lixarkitug | Inhibitor | 99% | Unkown |
| HY-P99487 | Briobacept | 97.66% | Unkown | |
| HY-P991005 | Larnefpendekin alfa | Inhibitor | / | Unkown |
| HY-P990451 | Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) | Inhibitor | 95.01% | Unkown |
| HY-P990547 | APX-007 | Inhibitor | / | Unkown |
| HY-P990776 | Vimekofusp | / | Unkown | |
| HY-P991593 | ABT-147 | Inhibitor | / | Unkown |
| HY-P991600 | Anti-IL-6 Antibody (Chugai SK2) | Inhibitor | / | Unkown |
| HY-P992004 | KHK2805 | Inhibitor | / | Unkown |
| HY-P992028 | Anti-IL-1RA Antibody | Inhibitor | / | Unkown |
| HY-P992032 | TPP-9476 | Antagonist | / | Unkown |
| HY-P992161 | REGN-10597 | / | Unkown | |
| HY-P992235 | Anti-IL11RA Antibody (Hu16E12) | Inhibitor | / | Unkown |
| HY-P992239 | Anti-IL-18Rα Antibody | / | Unkown | |
| HY-P992246 | Anti-IL-27RA Antibody | / | Unkown | |
| HY-P99790 | Priliximab | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service